CD68 and neoplasm: In their recent retrospective study on 24 patients treated with Nivolumab and Ipilimumab, Kim et al. analyzed, using multiplexed immunohistochemistry, the tumor content of T cell subsets (CD8+ cytotoxic, Foxp3- CD4+ helper or regulatory T cells), B cells, macrophages (CD68+ CD206- M1, CD68+ CD206+ M2), and dendritic cells [41].